

Complete Summary

GUIDELINE TITLE

Practice guideline for the treatment of patients with bipolar disorder (revision).

BIBLIOGRAPHIC SOURCE(S)

Practice guideline for the treatment of patients with bipolar disorder (revision).
Am J Psychiatry 2002 Apr; 159(4 Suppl): 1-50. [472 references] [PubMed](#)

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously released version (Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994 Dec; 151[12 Suppl]: 1-36).

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse (NGC): This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

- On May 12, 2006, GlaxoSmithKline (GSK) and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of changes to the Clinical Worsening and Suicide Risk subsection of the WARNINGS section in the prescribing Information for Paxil and Paxil CR. These labeling changes relate to adult patients, particularly those who are younger adults.

A recent meta-analysis conducted of suicidal behavior and ideation in placebo-controlled clinical trials of paroxetine in adult patients with psychiatric disorders including Major Depressive Disorder (MDD), other depression and non-depression disorders. Results of this analysis showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo. Further, in the analysis of adults with MDD (all ages), the frequency of suicidal behavior was higher in patients treated with paroxetine compared with placebo. This difference was statistically significant; however, as the absolute number and incidence of events are small, these data should be interpreted with caution. All of the reported events of suicidal behavior in the adult patients with MDD were non-fatal suicide attempts, and the majority of these attempts (8 of 11) were in younger adults aged 18-30. These MDD data suggest that the higher frequency observed in the younger adult population across psychiatric disorders may extend beyond the age of 24.

It is important that all patients, especially young adults and those who are improving, receive careful monitoring during paroxetine therapy regardless of the condition being treated. See the [FDA Web site](#) for more information.

- On January 13, 2006, Novartis and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of revisions to the BOXED WARNING, WARNINGS, CONTRAINDICATIONS, PRECAUTIONS (Information for Patients and Pharmacokinetic-Related Interactions subsections), and ADVERSE REACTIONS (Postmarketing Clinical Experience subsection) sections of the prescribing information for Clozaril (clozapine) tablets. Recommendations from the FDA's Psychopharmacological Drugs Advisory Committee regarding the white blood cell monitoring schedule, required for all clozapine users, has resulted in modification in the monitoring schedule. Additional labeling changes address safety issues related to dementia-related psychosis, paralytic ileus, hypercholesterolemia and pharmacokinetic interaction with citalopram. See the [FDA Web site](#) for more information.
- On December 8, 2005, the U.S. Food and Drug Administration (FDA) has determined that exposure to paroxetine in the first trimester of pregnancy may increase the risk for congenital malformations, particularly cardiac malformations. At the FDA's request, the manufacturer has changed paroxetine's pregnancy category from C to D and added new data and recommendations to the WARNINGS section of paroxetine's prescribing information. FDA is awaiting the final results of the recent studies and accruing additional data related to the use of paroxetine in pregnancy in order to better characterize the risk for congenital malformations associated with paroxetine.

Physicians who are caring for women receiving paroxetine should alert them to the potential risk to the fetus if they plan to become pregnant or are currently in their first trimester of pregnancy. Discontinuing paroxetine therapy should be considered for these patients. Women who are pregnant, or planning a pregnancy, and currently taking paroxetine should consult with their physician about whether to continue taking it. Women should not stop the drug without discussing the best way to do that with their physician. See the [FDA Web site](#) for more information.

- On September 27, 2005, GlaxoSmithKline (GSK) and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of changes to the Pregnancy/PRECAUTIONS section of the Prescribing Information for Paxil and Paxil CR Controlled-Release Tablets to describe the results of a GSK retrospective epidemiologic study of major congenital malformations in infants born to women taking antidepressants during the first trimester of pregnancy. This study suggested an increase in the risk of overall major congenital malformations for paroxetine as compared to other antidepressants [OR 2.2; 95% confidence interval, 1.34-3.63]. Healthcare professionals are advised to carefully weigh the potential risks and benefits of using paroxetine therapy in women during pregnancy and to discuss these findings as well as treatment alternatives with their patients. See the [FDA Web site](#) for more information.
- On July 1, 2005, in response to recent scientific publications that report the possibility of increased risk of suicidal behavior in adults treated with antidepressants, the U.S. Food and Drug Administration (FDA) issued a Public

Health Advisory to update patients and healthcare providers with the latest information on this subject. Even before the publication of these recent reports, FDA had already begun the process of reviewing available data to determine whether there is an increased risk of suicidal behavior in adults taking antidepressants. The Agency has asked manufacturers to provide information from their trials using an approach similar to that used in the evaluation of the risk of suicidal behavior in the pediatric population taking antidepressants. This effort will involve hundreds of clinical trials and may take more than a year to complete. See the [FDA Web site](#) for more information.

- On April 19, 2005, Novartis Pharmaceuticals and the U.S. Food and Drug Administration (FDA) notified healthcare professionals about revisions to the WARNINGS and PRECAUTIONS sections of the prescribing information for TRILEPTAL (oxcarbazepine) tablets and oral suspension, indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ages 4-16 years with epilepsy. The updated WARNINGS section describes serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) that have been reported in both children and adults in association with Trileptal use. The PRECAUTIONS section has been updated to include language regarding multi-organ hypersensitivity reactions that have been reported in association with Trileptal use. See the [FDA Web site](#) for more information.

COMPLETE SUMMARY CONTENT

** REGULATORY ALERT **

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY

DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Bipolar disorder, including:

- Bipolar I disorder
- Bipolar II disorder
- Cyclothymic disorder
- Bipolar disorder not otherwise specified (NOS)

GUIDELINE CATEGORY

Evaluation
Management
Treatment

CLINICAL SPECIALTY

Family Practice
Internal Medicine
Psychiatry

INTENDED USERS

Physicians

GUIDELINE OBJECTIVE(S)

To assist the clinician faced with the task of implementing a specific regimen for the treatment of a patient with bipolar disorder

TARGET POPULATION

Primarily adults (18 years of age or older) with bipolar disorder

INTERVENTIONS AND PRACTICES CONSIDERED

Psychiatric management

1. Diagnostic evaluation
2. Evaluation of the safety of the patients and others and determination of a treatment setting
3. Establishment and maintenance of a therapeutic alliance
4. Monitoring of treatment response
5. Patient and family education
6. Measures to enhance treatment compliance
7. Promotion of awareness of stressors and regular patterns of activity and sleep
8. Work with patient to anticipate and address early signs of relapse
9. Evaluation and management of functional impairments

Somatic treatments

1. Pharmacologic agents:

Classes of medications:

- Antidepressants
 - Monoamine oxidase inhibitors (MAOIs)
 - Selective serotonin reuptake inhibitor (SSRI)
- Antipsychotics
- Benzodiazepines

Specific medications:

- Bupropion
 - Olanzapine
 - Carbamazepine
 - Clozapine
 - Lamotrigine
 - Lithium
 - Oxcarbazepine
 - Paroxetine
 - Risperidone
 - Valproate
 - Venlafaxine
2. Electroconvulsive therapy (ECT)
 3. Combination therapies

Concomitant psychosocial interventions (psychoeducational, interpersonal, family, group, social rhythm, psychodynamic, and cognitive behavior therapies)

MAJOR OUTCOMES CONSIDERED

- Efficacy of treatment as evidenced by morbidity and mortality associated with bipolar disorder
- Adverse effects of treatment

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

A computerized search of the relevant literature from MEDLINE and PsycINFO was conducted. Sources of funding were not considered when reviewing the literature.

The first literature search was conducted by searching MEDLINE and PsycINFO for the period from 1992 to 2000. Key words used were "bipolar disorder," "bipolar depression," "mania," "mixed states," "mixed episodes," "mixed mania," "antimanic," "hypomanic," "hypomania," "manic depression," "prophylactic," "pharmacotherapy," "mood stabilizers," "mood-stabilizing," "rapid cycling," "maintenance," "continuation," "child and adolescent," "antidepressants," "valproate," "lithium," "carbamazepine," "olanzapine," "risperidone," "gabapentin," "topiramate," "lamotrigine," "clonazepam," "divalproex," "psychotherapy," "family therapy," "psychoeducation," "course," "epidemiology," "comorbidity," "anxiety," "anxiety disorders," "attention deficit," "catatonia," "elderly," "family history," "gender," "general medical conditions," "life events," "personality disorders," "pregnancy," "psychosis," "stress," "substance-related disorders," "suicide," "homicide," and "violence."

An additional MEDLINE search for the period from 1992 to 2001 used the key words "genetic counseling," "family functioning," "cross-cultural issues," and "pharmacokinetics." A search on PubMed was also conducted through 2001 that used the search terms "electroconvulsive," "intravenous drug abuse," "treatment response," "pharmacogenetic," "attention deficit disorder," "violence," "aggression," "aggressive," "suicidal," "cognitive impairment," "sleep," "postpartum," "ethnic," "racial," "metabolism," "hyperparathyroidism," "overdose," "toxicity," "intoxication," "pregnancy," "breast-feeding," and "lactation."

Additional, less formal, literature searches were conducted by American Psychiatric Association (APA) staff and individual members of the work group on bipolar disorder.

NUMBER OF SOURCE DOCUMENTS

The first literature search yielded 3,382 citations

The additional MEDLINE search yielded 122 citations.

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Expert Consensus (Committee)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses
Systematic Review with Evidence Tables

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Once a topic is chosen for guideline development, a work group is formed to draft the guideline. By design, the work group consists of psychiatrists in active clinical practice with diverse expertise and practice experience relevant to the topic. Policies established by the Steering Committee guide the work of systematically reviewing data in the literature and forging consensus on the implications of those

data, as well as describing a clinical consensus. These policies, in turn, stem from criteria formulated by the American Medical Association to promote the development of guidelines that have a strong evidence base and that make optimal use of clinical consensus.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Each recommendation is identified as falling into one of three categories of endorsement, indicated by a bracketed Roman numeral following the statement. The three categories represent varying levels of clinical confidence regarding the recommendation:

[I] Recommended with substantial clinical confidence.

[II] Recommended with moderate clinical confidence.

[III] May be recommended on the basis of individual circumstances.

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

External Peer Review
Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

This practice guideline was developed under the auspices of the American Psychiatric Association Steering Committee on Practice Guidelines. The development process is detailed in a document available from the American Psychiatric Association Department of Quality Improvement and Psychiatric Services: the "American Psychiatric Association Guideline Development Process" (see "Companion Documents").

Key features of this process, relevant to review methodology, include the following:

- The production of multiple drafts with widespread review; seven organizations and more than 40 individuals (named in the original guideline document) submitted significant comments.
- Approval by the American Psychiatric Association Assembly and Board of Trustees. This guideline was approved in December 2001.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Each recommendation is identified as falling into one of three categories of endorsement, indicated by a bracketed Roman numeral following the statement. The three categories represent varying levels of clinical confidence regarding the recommendation.

Definition of grades of recommendation [I-III] are presented at the end of the "Major Recommendations" field.

Psychiatric Management

At this time, there is no cure for bipolar disorder; however, treatment can decrease the associated morbidity and mortality [I]. Initially, the psychiatrist should perform a diagnostic evaluation and assess the patient's safety and level of functioning to arrive at a decision about the optimum treatment setting [I]. Subsequently, specific goals of psychiatric management include establishing and maintaining a therapeutic alliance, monitoring the patient's psychiatric status, providing education regarding bipolar disorder, enhancing treatment compliance, promoting regular patterns of activity and of sleep, anticipating stressors, identifying new episodes early, and minimizing functional impairments [I].

Acute Treatment

Manic or Mixed Episodes

The first-line pharmacological treatment for more severe manic or mixed episodes is the initiation of either lithium plus an antipsychotic or valproate plus an antipsychotic [I]. For less ill patients, monotherapy with lithium, valproate, or an antipsychotic such as olanzapine may be sufficient [I]. Short-term adjunctive treatment with a benzodiazepine may also be helpful [II]. For mixed episodes, valproate may be preferred over lithium [II]. Atypical antipsychotics are preferred over typical antipsychotics because of their more benign side effect profile [I], with most of the evidence supporting the use of olanzapine or risperidone [II]. Alternatives include carbamazepine or oxcarbazepine in lieu of lithium or valproate [II]. Antidepressants should be tapered and discontinued if possible [I]. If psychosocial therapy approaches are used, they should be combined with pharmacotherapy [I].

For patients who, despite receiving maintenance medication treatment, experience a manic or mixed episode (i.e., a "breakthrough" episode), the first-line intervention should be to optimize the medication dose [I]. Introduction or resumption of an antipsychotic is sometimes necessary [II]. Severely ill or agitated patients may also require short-term adjunctive treatment with a benzodiazepine [I].

When first-line medication treatment at optimal doses fails to control symptoms, recommended treatment options include addition of another first-line medication [I]. Alternative treatment options include adding carbamazepine or oxcarbazepine in lieu of an additional first-line medication [II], adding an antipsychotic if not already prescribed [I], or changing from one antipsychotic to another [III]. Clozapine may be particularly effective in the treatment of refractory illness [II]. Electroconvulsive therapy may also be considered for patients with severe or treatment-resistant mania or if preferred by the patient in consultation with the

psychiatrist [1]. In addition, electroconvulsive therapy is a potential treatment for patients experiencing mixed episodes or for patients experiencing severe mania during pregnancy [11].

Manic or mixed episodes with psychotic features usually require treatment with an antipsychotic medication [11].

Depressive Episodes

The first-line pharmacological treatment for bipolar depression is the initiation of either lithium [1] or lamotrigine [11]. Antidepressant monotherapy is not recommended [1]. As an alternative, especially for more severely ill patients, some clinicians will initiate simultaneous treatment with lithium and an antidepressant [11]. In patients with life-threatening inanition, suicidality, or psychosis, electroconvulsive therapy also represents a reasonable alternative [1]. Electroconvulsive therapy is also a potential treatment for severe depression during pregnancy [11].

A large body of evidence supports the efficacy of psychotherapy in the treatment of unipolar depression [1]. In bipolar depression, interpersonal therapy and cognitive behavior therapy may be useful when added to pharmacotherapy [11]. While psychodynamic psychotherapy has not been empirically studied in patients with bipolar depression, it is widely used in addition to medication [11].

For patients who, despite receiving maintenance medication treatment, suffer a breakthrough depressive episode, the first-line intervention should be to optimize the dose of maintenance medication [11].

When an acute depressive episode of bipolar disorder does not respond to first-line medication treatment at optimal doses, next steps include adding lamotrigine [1], bupropion [11], or paroxetine [11]. Alternative next steps include adding other newer antidepressants (e.g., a selective serotonin reuptake inhibitor [SSRI] or venlafaxine) [11] or a monoamine oxidase inhibitor (MAOI) [11]. For patients with severe or treatment-resistant depression or depression with psychotic or catatonic features, electroconvulsive therapy should be considered [1].

The likelihood of antidepressant treatment precipitating a switch into a hypomanic episode is probably lower in patients with bipolar II depression than in patients with bipolar I depression. Therefore, clinicians may elect to recommend antidepressant treatment earlier in patients with bipolar II disorder [11].

Depressive episodes with psychotic features usually require adjunctive treatment with an antipsychotic medication [1]. Electroconvulsive therapy (ECT) represents a reasonable alternative [1].

Rapid Cycling

As defined in DSM-IV-TR and applied in this guideline, rapid cycling refers to the occurrence of four or more mood disturbances within a single year that meet criteria for a major depressive, mixed, manic, or hypomanic episode. These episodes are demarcated either by partial or full remission for at least 2 months

or a switch to an episode of opposite polarity (e.g., from a major depressive to a manic episode). The initial intervention in patients who experience rapid cycling is to identify and treat medical conditions, such as hypothyroidism or drug or alcohol use, that may contribute to cycling [I]. Certain medications, particularly antidepressants, may also contribute to cycling and should be tapered if possible [II]. The initial treatment for patients who experience rapid cycling should include lithium or valproate [I]; an alternative treatment is lamotrigine [I]. For many patients, combinations of medications are required [II].

Maintenance Treatment

Following remission of an acute episode, patients may remain at particularly high risk of relapse for a period of up to 6 months; this phase of treatment, sometimes referred to as continuation treatment, is considered in this guideline to be part of the maintenance phase. Maintenance regimens of medication are recommended following a manic episode [I]. Although few studies involving patients with bipolar II disorder have been conducted, consideration of maintenance treatment for this form of the illness is also strongly warranted [II]. The medications with the best empirical evidence to support their use in maintenance treatment include lithium [I] and valproate [I]; possible alternatives include lamotrigine [II] or carbamazepine or oxcarbazepine [II]. If one of these medications was used to achieve remission from the most recent depressive or manic episode, it generally should be continued [I]. Maintenance sessions of electroconvulsive therapy may also be considered for patients whose acute episode responded to electroconvulsive therapy [II].

For patients treated with an antipsychotic medication during the preceding acute episode, the need for ongoing antipsychotic treatment should be reassessed upon entering maintenance treatment [I]; antipsychotics should be discontinued unless they are required for control of persistent psychosis [I] or prophylaxis against recurrence [III]. While maintenance therapy with atypical antipsychotics may be considered [III], there is as yet no definitive evidence that their efficacy in maintenance treatment is comparable to that of agents such as lithium or valproate.

During maintenance treatment, patients with bipolar disorder are likely to benefit from a concomitant psychosocial intervention—including psychotherapy—that addresses illness management (i.e., adherence, lifestyle changes, and early detection of prodromal symptoms) and interpersonal difficulties [II].

Group psychotherapy may also help patients address such issues as adherence to a treatment plan, adaptation to a chronic illness, regulation of self-esteem, and management of marital and other psychosocial issues [II]. Support groups provide useful information about bipolar disorder and its treatment [I].

Patients who continue to experience subthreshold symptoms or breakthrough mood episodes may require the addition of another maintenance medication [II], an atypical antipsychotic [III], or an antidepressant [III]. There are currently insufficient data to support one combination over another. Maintenance sessions of electroconvulsive therapy may also be considered for patients whose acute episode responded to electroconvulsive therapy [II].

Refer to the original guideline document for a discussion of special clinical features influencing the treatment plan.

Definitions:

Grades of Recommendations:

- I. Recommended with substantial clinical confidence.
- II. Recommended with moderate clinical confidence.
- III. May be recommended on the basis of individual circumstances.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The recommendations are based on the best available data and clinical consensus with regard to a particular clinical decision. The summary of treatment recommendations is keyed according to the level of confidence with which each recommendation is made (see the "Major Recommendations" field). In addition, the following coding system is used to indicate the nature of the supporting evidence in the references:

- [A] Randomized clinical trial
- [B] Clinical trial
- [C] Cohort or longitudinal study
- [D] Case-control study
- [E] Review of secondary analysis
- [F] Review
- [G] Other

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Benefits of treatment in general include decreased frequency, severity, and psychosocial consequences of episodes; and improved psychosocial functioning between episodes.
- Potential benefits of psychiatric management include treatment of acute exacerbations; prevention of recurrences; improved interepisode functioning; the provision of assistance, insight, and support to the patient and family; and the reduction of the morbidity and sequelae of bipolar disorder.
- Potential benefits of pharmacologic treatments include the effective treatment of acute episodes; decreased symptoms of mania or depression; the prevention of future episodes; and mood-stabilizing effects.
- Electroconvulsive therapy (ECT) is efficacious in the treatment of both phases of bipolar disorder.

POTENTIAL HARMS

Side effects and toxicities of medications

- **Lithium.** Dose-related side effects of lithium include polyuria, polydipsia, weight gain, cognitive problems (e.g., dulling, impaired memory, poor concentration, confusion, mental slowness), tremor, sedation or lethargy, impaired coordination, gastrointestinal distress (e.g., nausea, vomiting, dyspepsia, diarrhea), hair loss, benign leukocytosis, acne, and edema. Lithium may cause benign electrocardiogram (ECG) changes associated with repolarization. Less commonly, cardiac conduction abnormalities have been associated with lithium treatment. The most common renal effect of lithium is impaired concentrating capacity caused by reduced renal response to antidiuretic hormone (ADH), manifested as polyuria, polydipsia, or both. Although the polyuria associated with early lithium treatment may resolve, persistent polyuria (ranging from mild and well tolerated to severe nephrogenic diabetes insipidus) may occur. In addition to the other signs and symptoms of hypothyroidism, patients with bipolar disorder are at risk of developing depression or rapid cycling. Hyperparathyroidism has also been noted with lithium treatment. A small number of case reports have described exacerbation or first occurrences of psoriasis associated with lithium treatment. Approximately 10% to 20% of patients receiving long-term lithium treatment (i.e., for more than 10 years) display morphological kidney changes, usually interstitial fibrosis, tubular atrophy, and sometimes glomerular sclerosis. Additionally, several studies have shown that a small percentage of patients treated with lithium may develop rising serum creatinine concentrations after 10 years or more of treatment.

Signs and symptoms of early lithium intoxication (with levels above 1.5 meq/liter) include marked tremor, nausea and diarrhea, blurred vision, vertigo, confusion, and increased deep tendon reflexes. With lithium levels above 2.5 meq/liter, patients may experience more severe neurological complications and eventually experience seizures, coma, cardiac dysrhythmia, and permanent neurological impairment.

- **Valproate.** Common dose-related side effects of valproate include gastrointestinal distress (e.g., anorexia, nausea, dyspepsia, vomiting, diarrhea), benign hepatic transaminase elevations, osteoporosis, tremor, and sedation. Mild, asymptomatic leukopenia and thrombocytopenia occur less frequently and are reversible upon drug discontinuation. Other side effects that are often bothersome to the patient include hair loss, increased appetite, and weight gain. Polycystic ovarian syndrome may be possible with valproate treatment. Rare, idiosyncratic, but potentially fatal adverse events with valproate include irreversible hepatic failure, hemorrhagic pancreatitis, and agranulocytosis. Signs of overdose include somnolence, heart block, and eventually coma. Deaths have been reported. Overdose can be treated with hemodialysis.
- **Carbamazepine.** The most common dose-related side effects of carbamazepine include neurological symptoms, such as diplopia, blurred vision, fatigue, nausea, and ataxia. These effects are usually transient and often reversible with dose reduction. Less frequent side effects include skin rashes, mild leukopenia, mild thrombocytopenia, hyponatremia, and (less

commonly) hypo-osmolality. Mild liver enzyme elevations occur in 5% to 15% of patients. Hyponatremia occurs in 6% to 31% of patients, is rare in children but probably more common in the elderly, occasionally develops many months after the initiation of carbamazepine treatment, and sometimes necessitates carbamazepine discontinuation. In addition, carbamazepine may decrease total and free thyroxine levels and increase free cortisol levels, but these effects are rarely clinically significant. Weight gain is also a common side effect of carbamazepine. Rare, idiosyncratic, but serious and potentially fatal side effects of carbamazepine include agranulocytosis, aplastic anemia, thrombocytopenia, hepatic failure, exfoliative dermatitis (e.g., Stevens-Johnson syndrome), and pancreatitis. Although these side effects usually occur within 3 to 6 months of carbamazepine initiation, they have also occurred after more extended periods of treatment. Other rare side effects include systemic hypersensitivity reactions, cardiac conduction disturbances, psychiatric symptoms (including sporadic cases of psychosis), and, very rarely, renal effects (including renal failure, oliguria, hematuria, and proteinuria). Carbamazepine may be fatal in overdose; deaths have been reported with ingestions of more than 6 grams. Signs of impending carbamazepine toxicity include dizziness, ataxia, sedation, and diplopia. Acute intoxication can result in hyperirritability, stupor, or coma. The most common symptoms of carbamazepine overdose are nystagmus, ophthalmoplegia, cerebellar and extrapyramidal signs, impaired consciousness, convulsions, and respiratory dysfunction. Cardiac symptoms may include tachycardia, arrhythmia, conduction disturbances, and hypotension. Gastrointestinal and anticholinergic symptoms may also occur.

- Olanzapine. In placebo-controlled clinical trials, somnolence was the most common side effect associated with olanzapine. Other common side effects included constipation, dry mouth, increased appetite, and weight gain. Especially during initial dose titration, olanzapine may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope. Syncope was reported in 0.6% of olanzapine-treated patients in phase II and III trials. In clinical trials, seizures occurred in 0.9% of olanzapine-treated patients. Transient elevations in plasma prolactin concentrations were also observed in short-term trials. Clinically significant hepatic transaminase elevations (≥ 3 times the upper limit of the normal range) were observed in 2% of olanzapine-treated patients.
- Lamotrigine. The most common side effects of lamotrigine in the treatment of depression are headache, nausea, infection, and xerostomia. The risk of serious rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis, was approximately 0.3% in adults and approximately 1% in children in clinical trials for epilepsy. However, with a slow titration schedule, the risk of serious rash was reduced to 0.01% in adults, which is comparable to that of other anticonvulsant medications. Rash can occur at any time during treatment but is more likely to occur early in treatment. It may also be more likely if lamotrigine and valproate are administered concomitantly. Whenever lamotrigine is prescribed, patients should be apprised of the risk of rash and urged to contact the psychiatrist or primary care physician immediately if a rash occurs. At rash onset, it is difficult to distinguish between a serious and a more benign rash. Particularly worrisome are rashes accompanied by fever or sore throat, those that are diffuse and widespread, and those with prominent facial or mucosal involvement. In such circumstances lamotrigine (and concurrent valproate) should be discontinued. With concurrent valproate treatment, pharmacokinetic interactions lead to

lamotrigine levels that are approximately twice normal. To minimize the risk of potentially serious rash in patients who are receiving valproate, the dose schedule should be cut in half (i.e., 12.5 mg/day or 25 mg every other day for 2 weeks, then 25 mg/day for weeks 3 and 4). Similarly, concurrent carbamazepine treatment leads to an increase in lamotrigine metabolism and requires dosing to be doubled.

Note: For information on side effects of electroconvulsive therapy (ECT), refer to the American Psychiatric Association Task Force Report on ECT (The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging: a Task Force report of the American Psychiatric Association, 2nd ed. Washington [DC]: American Psychiatric Press, 2001; Available from the [American Psychiatric Association Web site](#)).

For information on side effects of antidepressants, see the related National Guideline Clearinghouse (NGC) summary of the American Psychiatric Association guideline [Practice Guideline for the Treatment of Patients With Major Depressive Disorder](#).

Subgroups Most Likely to be Harmed:

- Women taking lithium are more likely to experience hypothyroidism than men.
- Patients taking valproate who have had or currently have hepatic disease may be at greater risk for hepatotoxicity when taking valproate.
- Elderly patients may be more sensitive to side effects of carbamazepine.
- Patients with a history of seizure disorder or in clinical conditions associated with lowered seizure threshold are more likely to experience seizures when taking olanzapine.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

This report is not intended to be construed or to serve as a standard of medical care. Standards of medical care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and practice patterns evolve. These parameters of practice should be considered guidelines only. Adherence to them will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgment regarding a particular clinical procedure or treatment plan must be made by the psychiatrist in light of the clinical data presented by the patient and the diagnostic and treatment options available.

This practice guideline has been developed by psychiatrists who are in active clinical practice. In addition, some contributors are primarily involved in research or other academic endeavors. It is possible that through such activities some contributors have received income related to treatments discussed in this guideline. A number of mechanisms are in place to minimize the potential for producing biased recommendations due to conflicts of interest. The guideline has

been extensively reviewed by members of American Psychiatric Association as well as by representatives from related fields. Contributors and reviewers have all been asked to base their recommendations on an objective evaluation of available evidence. Any contributor or reviewer who has a potential conflict of interest that may bias (or appear to bias) his or her work has been asked to notify the American Psychiatric Association Department of Quality Improvement and Psychiatric Services. This potential bias is then discussed with the work group chair and the chair of the Steering Committee on Practice Guidelines. Further action depends on the assessment of the potential bias.

The cross-sectional (i.e., current clinical status) and longitudinal (i.e., frequency, severity, and consequences of past episodes) context of the treatment decision should guide the psychiatrist and bipolar disorder patient in choosing from among various possible treatments and treatment settings. Such treatment decisions must be based on knowledge of the potential beneficial and adverse effects of available options along with information about patient preferences. In addition, treatment decisions should be continually reassessed as new information becomes available, the patient's clinical status changes, or both.

Distinctions in Types of Bipolar Disorder

Every effort has been made to identify and highlight distinctions between bipolar I and bipolar II disorder in terms of patient response to treatment. However, with few exceptions, data from large trials have been presented in such a way that making such distinctions is difficult. For the treatment of patients with major depressive disorder, see the related National Guideline Clearinghouse (NGC) summary of the American Psychiatric Association guideline [Practice Guideline for the Treatment of Patients With Major Depressive Disorder](#).

Psychotherapy

There have been no definitive studies to date of psychotherapy in lieu of antidepressant treatment for bipolar depression.

Treatment of Adolescents with Bipolar Disorder

To date, there has been only one double-blind, placebo-controlled, randomized study of pharmacotherapy in the treatment of adolescents with bipolar disorder. The majority of information available about pharmacological treatments for bipolar disorder in youth relies upon open studies, case series, and case reports.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

The American Psychiatric Association develops derivative products including patient guides, quick reference guides, and quality of care indicators with research studies to evaluate the effectiveness of the guideline.

IMPLEMENTATION TOOLS

Staff Training/Competency Material

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better

IOM DOMAIN

Effectiveness
Patient-centeredness
Safety

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Practice guideline for the treatment of patients with bipolar disorder (revision).
Am J Psychiatry 2002 Apr; 159(4 Suppl): 1-50. [472 references] [PubMed](#)

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1994 Dec (revised 2002 Apr)

GUIDELINE DEVELOPER(S)

American Psychiatric Association - Medical Specialty Society

SOURCE(S) OF FUNDING

American Psychiatric Association (APA)

GUIDELINE COMMITTEE

Work Group on Bipolar Disorder

Steering Committee on Practice Guidelines

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Work Group on Bipolar Disorder: Robert M.A. Hirschfeld, MD, Chair; Charles L. Bowden, MD; Michael J. Gitlin, MD; Paul E. Keck, MD; Roy H. Perlis, MD; Trisha Suppes, MD, PhD; Michael E. Thase, MD; Karen D. Wagner, MD

Steering Committee on Practice Guidelines: John S. McIntyre, MD; Chair; Sara C. Charles, MD; Vice-Chair; Kenneth Z. Altshuler, MD; Ian Cook, MD; C. Deborah Cross, MD; Barry J. Landau, MD; Louis Alan Moench, MD; Stuart W. Twemlow, MD; Sherwyn Woods, MD, PhD; Joel Yager, MD

Consultants and Liaisons: Paula Clayton, MD (Consultant); Marcia Goin, MD, PhD (Liaison); Marion Goldstein, MD (Liaison); Sheila Hafter Gray, MD (Consultant); Andrew J. Kolodny, MD (Liaison); Margaret T. Lin, MD (Liaison); Grayson Norquist, MD (Consultant); Susan Stabinsky, MD (Consultant); Robert Johnston, MD (Area I); James Nininger, MD (Area II); Roger Peele, MD (Area III); Daniel Anzia, MD (Area IV); R. Scott Benson, MD (Area V); Lawrence Lurie, MD (Area VI); R. Dale Walker, MD (Area VII)

Staff: Rebecca M. Thaler, MPH, CHES, Senior Project Manager; Robert Kunkle, MA, Project Manager; Althea Simpson, Project Coordinator; Laura J. Fochtman, MD, Medical Editor; Claudia Hart, Director, Department of Quality Improvement and Psychiatric Services; Lloyd I. Sederer, MD, Director, Division of Clinical Services

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

This practice guideline has been developed by psychiatrists who are in active clinical practice. In addition, some contributors are primarily involved in research or other academic endeavors. It is possible that through such activities many contributors have received income related to treatments discussed in this guideline. A number of mechanisms are in place to minimize the potential for producing biased recommendations due to conflicts of interest. The guideline has been extensively reviewed by members of American Psychiatric Association (APA) as well as by representatives from related fields. Contributors and reviewers have all been asked to base their recommendations on an objective evaluation of the available evidence. Any contributor or reviewer who has a potential conflict of interest that may bias (or appear to bias) his or her work has been asked to notify the APA Office of Research. This potential bias is then discussed with the work group chair and the chair of the Steering Committee on Practice Guidelines. Further action depends on the assessment of the potential bias.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously released version (Practice guideline for the treatment of patients with bipolar disorder. *Am J Psychiatry* 1994 Dec; 151[12 Suppl]: 1-36).

GUIDELINE AVAILABILITY

Electronic copies: Available from the [American Psychiatric Association Web site](#).

Print copies: Available from the American Psychiatric Press, Inc (APPI), 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901; (703) 907-7322; (800) 368-5777; Fax (703) 907-1091.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

- American Psychiatric Association practice guideline development process. In: practice guidelines for the treatment of psychiatric disorders: compendium 2000. Washington (DC): American Psychiatric Press, Inc (APPI), 2000.

Print copies: Available from the American Psychiatric Press, Inc (APPI), 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901; (703) 907-7322; (800) 368-5777; Fax (703) 907-1091.

Additionally, a continuing medical education (CME) course is available online at the [American Psychiatric Association Web site](#).

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on December 1, 1998. The information was verified by the guideline developer on January 11, 1999. This summary was updated by ECRI on April 17, 2002. The information was verified by the guideline developer on July 24, 2002. This summary was updated by ECRI on April 21, 2005 following the release of a public health advisory from the U.S. Food and Drug Administration (FDA) regarding Trileptal (oxcarbazepine). This summary was updated by ECRI on August 15, 2005, following the U.S. Food and Drug Administration advisory on antidepressant medications. This summary was updated by ECRI on October 3, 2005, following the U.S. Food and Drug Administration advisory on Paxil (paroxetine). This summary was updated by ECRI on December 12, 2005, following the U.S. Food and Drug Administration advisory on Paroxetine HCL - Paxil and generic paroxetine. This summary was updated by ECRI on January 18, 2006, following the U.S. Food and Drug Administration advisory on Clozaril (clozapine). This summary was updated by ECRI on May 31, 2006 following the U.S. Food and Drug Administration advisory on Paxil (paroxetine hydrochloride).

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. For further information please contact the American Psychiatric Association, 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901; (703) 907-7322.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006

